To analyse skewed cost data, including zero costs, we applied hurdle regression.
| INTRODUC TI ON
Severe haemophilia A (FVIII: C < 0.01 IU/mL) is a congenital X-linked bleeding disorder resulting in spontaneous and trauma-induced bleeds, especially in joints. Prophylactic replacement therapy with clotting factor VIII (FVIII) concentrates has augmented the prevention of the development of haemophilic arthropathy 459 1 ; 460 2 . It offers patients a near-normal life with a life expectancy similar to that of males in the general population 461. 3 Prophylactic FVIII treatment also associates with a decreased inhibitor development risk 413. 4 Hence, early regular prophylaxis is the standard of care in children with severe haemophilia. Haemophilia treatment costs are high, with high-dose prophylaxis accounting for 95%-99.6% of the total 500 5 ; 455. 6 The predicted annual total treatment costs for an average-weight (74 kg) adult noninhibitor patient exceed US$ 298 000. Paediatric cost studies with real-world data are few;
an estimate of the average total annual costs of treating patients is US$ 21 600 for young children and US$ 124 000 for teenagers 469 7 ; 464 8 ; 472. 9 Most treatment cost reports are per patient and usually not per body weight, which challenges the cost comparisons.
This is typical among different paediatric studies where patient body weight varies significantly, and yet dosing is based on weight.
In Finland, the treatment of all children with severe haemophilia either in comprehensive care or haemophilia treatment centres in university hospitals follows a uniformly agreed protocol. Here, it has been a standard practice for nearly 2 decades to start primary prophylaxis with a recombinant FVIII (rFVIII) for all patients below age one, mainly via a central venous access device (CVAD) without increasing the risk of inhibitor development 465 10 ; 452. 11 With a long follow-up, this nationwide study evaluated the long-term realworld outcomes and yearly patient weight-based total costs in previously untreated patients (PUPs) with severe haemophilia A with and without inhibitors. We also included the costs of immune tolerance induction (ITI). We hope the study will pave the way to uniform documentation of treatment costs of paediatric haemophilia. The study involved 5 Finnish paediatric Haematology-Oncology tertiary centres (Kuopio, Oulu, Turku, Tampere and Helsinki University Hospitals), which serve also as treatment centres of haemophilia for children and adolescents.
| MATERIAL S AND ME THODS

| Design and setting
The Research Ethics committee of Northern Savo, Finland, provided a favourable opinion for this study (26//2010) . We obtained permissions to use the register data from each organization concerned. 
| Data extraction
| Prophylaxis
Detailed individual data on prophylaxis included age, type of venous access, number of exposure days and previous joint bleeds at the onset of prophylaxis. It also included the annual prophylactic regimen for every patient including body weight, dosage and frequency of prophylactic FVIII administrations. "Regular prophylaxis" was defined as long-term uninterrupted administration of an FVIII concentrate at least once a week to prevent bleeds. "Primary prophylaxis" meant regular prophylaxis started before age 2 and before the onset of any joint bleed. "Secondary prophylaxis" covers all other longterm prophylactic regular treatments failing to fulfil the criteria of primary prophylaxis.
| Clinical outcomes and bleeding episodes
We observed the number of annual bleeds including joint bleeds and the number of patients with a target joint or an arthropathy. We calculated the annualized bleeding rate (ABR) and the annualized joint bleeding rate (AJBR) as the number of (joint) bleeding episodes divided by the length of follow-up time in years. We recorded all major and minor bleeds requiring hospitalization. We based our definition of a major bleed in surgical and nonsurgical settings on ISTH recommendations 453 13 ; 418. 14 A joint bleed meant an episode characterized by an unusual sensation or "aura" in the joint in combination with any of the following signs: (i) increasing swelling or warmth of the skin over the joint, (ii) increasing pain, and (iii) progressive loss of range or difficulty in using the limb as compared to the baseline 447 15 ; 448. 16 In infants and young children, a joint bleed meant reluctance to use the limb accompanied with either pain, or swelling or warmth of the skin over the joint.
A target joint was defined as 3 or more spontaneous bleeds in a single joint within 6 consecutive months 447 15 ; 448. 16 
| Validation
To validate the FVIII consumption data extracted from the medical records, we acquired a patient-specific validation sample from the 
Inhibitor development
Patients who developed inhibitors (%) 13 ( 
| RE SULTS
| Patient characteristics
The final study sample included 62 PUPs with severe haemophilia A.
We excluded 7 patients: 4 immigrants were PTPs, previously treated with an unknown amount of an unidentified factor concentrate and blood components for bleeds, and 3 children had less than 75 exposure days. One child with a severe immunodeficiency, a chronic granulomatous disease, was included in the study, without recording the costs unrelated to haemophilia care, such as costs related to the treatment at the stem cell transplantation unit. The patients
were not diagnosed with any other severe conditions or bleeding disorders.
The median follow-up time for these patients was 12.7 years (range 1.2-19.3), with a cumulative follow-up time of 698 personyears. During the follow-up, 13 (21%) children developed a clinically significant inhibitor, 10 (16%) a high-titre one. Table 1 shows the baseline characteristics of the study population.
| Treatment
All our patients were on regular prophylaxis. 
| Validation
When comparing the annual prophylactic FVIII consumption ex- rate; ABR was 0.16 in noninhibitor patients; whereas in inhibitor patients it was 0.49 (P < .001). AJBR was 0.06 in noninhibitor patients, and in inhibitor patients it was 0.15 (P = .26).
| Long-term clinical outcomes
In contrast, ABR and AJBR were 3-to 4-fold lower among pri- Ten (16%) patients developed a target joint; 4 (6%) children developed chronic arthropathy, 2 of them requiring synovectomy. The incidence of a target joint or an arthropathy at the end of follow-up was 18% and 8% in noninhibitor patients and 8% and 0% in inhibitor patients (NS). Between children with primary or secondary prophylaxis, the incidence of a target joint or an arthropathy did not differ.
During these 698 patient-years of follow-up, our 62 subjects suf- 
| Long-term economic outcomes
During the 698 patients-years of follow-up, the mean (SD) annual treatment costs were 97 005€ (65 465), per patient and 4391€
(3852) per weight kg. These mean annual weight-adjusted costs were 2.8-fold (95% CI 1.9-4.1) higher in the case of inhibitor patients.
For patients without an inhibitor, they were 3154€ (95% CI, 2887-3446); whereas for patients with an inhibitor, they were 8691€ (95% CI, 6142-12 298, P < .01). Thereafter, they gradually decreased to 2246€ per kg (95% CI 1717-2857) at the age of 18. Mean annual total costs between prophylactic regimens were about the same: 4437€ per kg (95% CI 3431-5738) for patients with primary prophylaxis and 4183€ per kg (95% CI 3170-5519, P = .76) for those with secondary prophylaxis. The proportion of costs related to hospitalizations and outpatient visits were 51% for age 0 and 11% for age 1. However, since age 2, clotting factor consumption dominated costs, accounting for over 94% of the total costs. The group using the trough level guidance (n = 11) exhibited a
All patients, n = 62
Non-inhibitor patients, n = 49
Patients with an inhibitor history, n = 13 P Patients with 0 joint bleed, n (%)
25 (40) 21 (43) 4 (31) .32
Patients with 1 joint bleed, n (%)
15 (24) 12 (25) 3 (23) Patients with 2 joint bleeds, n (%) 4 (7) 3 (6) 1 (8) Patients with ≥3 joint bleeds, n (%)
18 (29) 13 (26) 5 (38) Patients with a target joint, n (%)
10 (16) 9 (18) 1 (8) .68
Patients with arthropathy, n (%)
4 (6) 4 (8) After ITI completion, the mean monthly €/kg costs decreased to 316
(97), nearly as low as in noninhibitor patients (mean, 275, SD, 76).
The expected payback period on ITI completion was 1.81 (95% CI 0.62-12.12) years, which indicates a relative short payback period in terms of annual cost savings.
| D ISCUSS I ON
Our study demonstrated that regular high-dose prophylactic treatment of PUPs with severe haemophilia A leads to excellent long-term clinical outcomes: both ABR and AJBR were very low. In patients with inhibitor development, early childhood ITI therapy was successful in terms of joint bleed rates; no difference existed between noninhibitor patients and patients with inhibitors. Early childhood ITI, regardless of its high initial costs, seems as a cost-neutral option in the long run, in fact already in <2 years, that is when comparing a hypothetical treatment strategy with the use of prophylactic or ondemand therapy with bypassing agents.
To the best of our knowledge, this study is the first of its kind using real-world data to examine the long-term clinical and economic outcomes of regular prophylactic treatment of PUPs with severe haemophilia A. We included inhibitor patients and provide data on costs per body weight, representing nearly 700 patient-years of follow-up. All our patients were on early regular prophylaxis started at the median age of 11.8 months. The median (IQR) annual FVIII consumption in prophylaxis was 4136 IU/kg (3250-5113). During the long follow-up (median 12.7 years), 40% of our patients experienced no joint bleed; over two-thirds (71%) experienced fewer than 3 joint bleeds. At the end of the follow-up, only 4 children had a target joint, which developed into chronic arthropathy. Thirteen (21%) patients developed a clinically significant inhibitor.
The mean (SD) overall total annual treatment costs per patient were 4391€/kg (3852). All patients who completed ITI achieved tolerance with complete (36%) or partial (64%) success. The mean (SD) total costs for ITI were 383 448€ (259 085), and at ages 1-3, ITI accounted for more than half of the total costs; whereas at age above 3, prophylactic FVIII treatment dominated.
A few long-term outcome studies of adult noninhibitor patients with regular prophylaxis have reported both clotting factor costs for prophylaxis and other healthcare costs such as surgery, hospitalizations and healthcare visits 500 5 ; 455. 6 Most paediatric studies report only the costs of prophylaxis 460 2 ; 459, 1 and resource utilization and related costs are only estimated with hypothetical patients 456, 22 without real-world data, which were the source of our approach. Although our study is retrospective, its advantages include long follow-up time, the uniform guidelines in Finnish paediatric haemophilia care, and the inclusion of national data of all consecutive PUPs during the 19-year study period, and all treatment costs covering the neonatal period to adolescence. Finland has centralized patient care to university hospitals, and our national haemophilia expert team of paediatric haematologists has unanimously agreed upon recommendations for treatment, prophylaxis and ITI.
In addition, our study analyses real-world data with a top-down costing approach, reporting patient and body weight-adjusted costs.
Simultaneous patient-specific data from the Finnish Prescription At the end of follow-up, patients were relative young (median age, 12.7 years). However, early childhood, in particularly, is the critical treatment period, affecting long-term joint health and quality of life in adulthood. The best long-term joint outcome is achieved starting primary prophylaxis at the earliest age [25] [26] [27] even before the first joint bleed compared with the strategy starting secondary prophylaxis after one or more joint bleeds. The number of joint bleeds before starting prophylaxis has a stronger association with the outcome than the age upon starting prophylaxis. 28 In all, with our results of scarce joint bleeds during childhood, we assume good long-term joint health reaching also to adulthood.
The prophylactic FVIII dosing regimen in Finland corresponds to the high-dose Swedish one 458 29 ; 499 30 ; 462. 31 Although prophylaxis in Finland is implemented mainly via central venous devices, the need for hospitalization was uncommon; costs related to hospitalizations and outpatient visits constituted less than 6% of the total costs beyond 1 year of age. The quality of life was beneficial:
regarding joint health and practical prophylaxis via ports at home.
In addition, the patient age at home treatment start was low (me- on-demand or prophylaxis with bypassing agents 457. 24 In our study, after inhibitor detection, direct monthly total costs €/kg quintupled from 259€ to 1473€ mainly due to the use of bypassing agents, corresponding to an annual total cost of 1.3 million € for an average weight (75 kg) adult. During ITI, costs further doubled to 3097€, but after successful ITI, the FVIII consumption of prophylaxis and total costs decreased to the level of noninhibitor patients. The expected payback period estimate of <2 years indicated that, ITI appears cost-neutral (ie, compared to on-demand or prophylaxis with bypassing agents) after a relatively short period: the savings of successful ITI, fully offset the incremental costs due to FVIII used for ITI during the 1.81 years.
However, this estimate based on the small number of patients with ITI and should be interpreted with caution. The mean (SD) cost for ITI was 383 448€ (259 085) during early childhood, but it increased ten-fold by age 14 (3 483 120€). Without prospective randomized trial confirming that treatment delay confers benefit, the current practice has been to delay the start of ITI until the inhibitor titre is <10 BU/mL with anticipated enhanced success. In a retrospective study in 2 U.S.
haemophilia treatment centres, a titre >10 BU/mL at ITI start did not impact the outcome in subjects with ITI initiation within 1 month of detection 470. 33 Also, health economic consequences emphasize the importance of prompt ITI regardless of the inhibitor titre.
As the use of new extended half-life (EHL) factor concentrates is increasing, our study with reliable data about real-world practices is crucial for the future, to critically compare long-term costs (and potential benefit) between the current and the future treatment options. The data provide relevant information to support decisionmaking related to new and usually even more expensive treatments, including EHL products, the bispecific antibody recognizing FIX and FX, and gene therapy.
Our earlier results have emphasized the role of early primary prophylaxis via ports to prevent major bleeds and decrease inhibitor incidence 452. 11 Our current study demonstrates that early highdose prophylaxis provides excellent long-term clinical outcomes.
Moreover, rapid ITI therapy during early childhood is successful and seems cost-neutral due to its relatively short expected payback period.
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